Ultragenyx Pushes Toward Profitability in 2027, Led by Pruned Pipeline, Layoffs

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock is trading lower on Wednesday after the company initiated substantial expense reductions to align expenses with revenue and achieve profitability by 2027.

Strategic Workforce Reduction And Expense Targets

The rare disease-focused company said on Tuesday that it is shifting its focus to commercial execution and a more targeted R&D strategy following the completion of several late-stage development programs, including its first-ever FDA approvals for glycogen storage disease type Ia (GSDIa) and Sanfilippo syndrome type A.

To support the transition, the company plans to reduce its workforce by approximately 20% to around 1,000 employees and lower operating expenses.

It expects 2027 R&D expenses to fall below $350 million and SG&A expenses to fall below $375 million.

Commercial Launch Priorities And Focused R&D Strategy

Ultragenyx will prioritize the commercial launches of Genglycos and Fayuvi, while continuing to grow revenue from existing products.

R&D spending will focus on generating primary data from the responder endpoint in the ongoing Phase 3 DTX301 study for ornithine transcarbamylase deficiency, assessing a potential development path for UX143 (setrusumab) for osteogenesis imperfecta, and advancing select early-stage programs toward future IND filings.

The restructuring is expected to result in approximately $25 million in severance and other one-time charges in the fourth quarter of 2026, with workforce reductions largely completed by year-end.

Ultragenyx continues to expect full-year GAAP profitability in 2027 and beyond.

Discontinuation Of Wilson Disease And Angelman Syndrome Trials

Ultragenyx will discontinue UX701 (rivunatpagene miziparvovec), its AAV9 gene therapy candidate for Wilson disease, after additional data from the dose-finding stage of the Phase 1/2 Cyprus2+ study failed to support advancement into a pivotal Phase 3 trial.

Although the fourth dosing cohort and other study data showed clinical activity in some patients, the results did not meet the company’s criteria for a majority of patients to achieve a biochemical response and discontinue standard-of-care treatment. UX701 demonstrated a favorable safety profile across all treated cohorts.

The company will wind down all ongoing studies for GTX-102 for Angelman syndrome. In September, the Phase 3 data showed that the trial missed its primary endpoint, which measured the change from baseline in the Bayley-4 cognitive raw score.

Q3 Financial Results, Priority Review Voucher Sales, And Guidance

Ultragenyx on Tuesday reported a third-quarter loss of $1.16, missing the consensus loss of $1.12.

Sales were $173 million, missing the Wall Street estimate of $183.118 million.

In October 2026, the company entered into two definitive agreements to sell the priority review vouchers (PRVs) received upon the approval of Genglycos and Fayuvi for a combined price of $413 million.

Ultragenyx reaffirmed its fiscal 2026 sales guidance of $730 million-$760 million compared to the consensus of $762.256 million.

The guidance excludes revenue from the launches of Fayuvi and Genglycose and includes Crysvita revenue of $500-$520 million and Dojolvi sales of $100-$110 million.

RARE Price Action: Ultragenyx Pharmaceutical shares were down 3.67% at $16.02 during premarket trading on Wednesday, according to Benzinga Pro data.

Photo: Shutterstock